We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
CVRx Inc. (developing the Rheos system to control hypertension) has raised $84mm through the closing of its Series E venture round. New Enterprise Associates and Johnson & Johnson Development Corp. co-led the financing and were joined by current backers BBT Fund, Thomas Weisel Healthcare Venture Partners, InterWest Partners, Frazier Healthcare Ventures, and SightLine Partners. The company will use the funds to continue its pivotal trial to gain FDA approval for the Rheos device (it is already CE Marked in Europe) and to build a sales and marketing team prior to launching the product. CVRx has raised over $209mm since it was formed in 2001.
Deal Industry
Medical Devices
Medical Devices
Implantable Devices
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?